The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy of Nexium capsules in daily clinical usage for the patients who have been prescribed Nexium for "gastric ulcer", "duodenal ulcer", "anastomotic ulcer", "reflux oesophagitis", "non-erosive reflux disease", or "Zollinger-Ellison syndrome"
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Adverse Drug Reactions
Timeframe: Patients with gastric ulcer, anastomotic ulcer or Zollinger-Ellison syndrome: 8 weeks
Number of Adverse Drug Reactions
Timeframe: Patients with duodenal ulcer: 6 weeks
Number of Adverse Drug Reactions
Timeframe: Patients with reflux oesophagitis: 8 weeks
Number of Adverse Drug Reactions
Timeframe: Patients with non-erosive reflux disease: 4 weeks